Conditional expression of human acid β-glucosidase improves the visceral phenotype in a Gaucher disease mouse model

Journal of Lipid Research

Volumn 47, Issue 10, 2006, Pages 2161-2170

  Sun, Ying ^a   Quinn, Brian ^a   Xu, You Hai ^a   Leonova, Tatyana ^b,c   Witte, David P ^a   Grabowski, Gregory A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Department of Pediatrics ^*  (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCOSIDASE; GLUCOSYLCERAMIDE; PROSAPOSIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GAUCHER DISEASE; IN VIVO STUDY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE PRESERVATION; TRANSGENE;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOXYCYCLINE; FEMALE; GAUCHER DISEASE; GENE EXPRESSION; GLUCOSYLCERAMIDASE; HUMANS; LIPIDS; LIVER; LUNG; MALE; MICE; POINT MUTATION; SPLEEN; VISCERA;

EID: 33845577582     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M600239-JLR200     Document Type: Article

References (31)

1. Beutler, E., and G. A. Grabowski. 2001. Gaucher disease. In The Metabolic and Molecular Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 3635-3668.
2. Zhao, H., and G. A. Grabowski. 2002. Gaucher disease: perspectives on a prototype lysosomal disease. Cell. Mol. Life Sci. 59: 694-707.
3. Theophilus, B., T. Latham, G. A. Grabowski, and F. I. Smith. 1989. Gaucher disease: molecular heterogeneity and phenotype-genotype correlations. Am. J. Hum. Genet. 45: 212-225.
4. Volk, B. W., B. J. Wallace, and M. Adachi. 1967. Infantile Gaucher's disease: electron microscopic and histochemical studies of a cerebral biopsy. J. Neuropathol. Exp. Neurol. 26: 176-177.
5. Kolodny, E. H., M. D. Ullman, H. J. Mankin, S. S. Raghavan, J. Topol, and J. L. Sullivan. 1982. Phenotypic manifestations of Gaucherdisease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients. Prog. Clin. Biol. Res. 95: 33-65.
6. Grabowski, G. A., and R. J. Hopkin. 2003. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu. Rev. Genomics Hum. Genet. 4: 403-436.
7. Brady, R. O. 2006. Enzyme replacement for lysosomal diseases. Annu. Rev. Med. 57: 283-296.
8. Desnick, R. J. 2004. Enzyme replacement and enhancement therapies for lysosomal diseases. J. Inherit. Metab. Dis. 27: 385-410.
9. Rorman, E. G., V. Scheinker, and G. A. Grabowski. 1992. Structure and evolution of the human prosaposin chromosomal gene. Genomics. 13: 312-318.
10. O'Brien, J. S., K. A. Kretz, N. Dewji, D. A. Wenger, F. Esch, and A. L. Fluharty. 1988. Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science. 241: 1098-1101.
11. Collard, M. W., S. R. Sylvester, J. K. Tsuruta, and M. D. Griswold. 1988. Biosynthesis and molecular cloning of sulfated glycoprotein 1 secreted by rat Sertoli cells: sequence similarity with the 70-kilodalton precursor to sulfatide/GM1 activator. Biochemistry. 27: 4557-4564.
12. Qi, X., and G. A. Grabowski. 2001. Molecular and cell biology of acid β-glucosidase and prosaposin. Prog. Nucleic Acid Res. Mol. Biol. 66: 203-239.
13. Furst, W., and K. Sandhoff. 1992. Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim. Biophys. Acta. 1126: 1-16.
14. Harzer, K., B. C. Paton, H. Christomanou, M. Chatelut, T. Levade, M. Hiraiwa, and J. S. O'Brien. 1997. Saposins (sap) A and C activate the degradation of galactosylceramide in living cells. FEBS Lett. 417: 270-274.
15. Fujita, N., K. Suzuki, M. T. Vanier, B. Popko, N. Maeda, A. Klein, M. Henseler, K. Sandhoff, and H. Nakayasu. 1996. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum. Mol. Genet. 5: 711-725.
16. Hulkova, H., M. Cervenkova, J. Ledvinova, M. Tochackova, M. Hrebicek, H. Poupetova, A. Befekadu, L. Berna, B. C. Paton, K. Harzer, et al. 2001. A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation. Hum. Mol. Genet. 10: 927-940.
17. Paton, B. C., B. Schmid, B. Kustermann-Kuhn, A. Poulos, and K. Harzer. 1992. Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase. Biochem. J. 285: 481-488.
18. Sun, Y., X. Qi, and G. A. Grabowski. 2003. Saposin C is required for normal resistance of acid β-glucosidase to proteolytic degradation. J. Biol. Chem. 278: 31918-31923.
19. Sun, Y., B. Quinn, D. P. Witte, and G. A. Grabowski. 2005. Gaucher disease mouse models: point mutations at the acid β-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J. Lipid Res. 46: 2102-2113.
20. Xu, Y. H., B. Quinn, D. Witte, and G. A. Grabowski. 2003. Viable mouse models of acid β-glucosidase deficiency: the defect in Gaucher disease. Am. J. Pathol. 163: 2093-2101.
21. Gossen, M., and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA. 89: 5547-5551.
22. Kistner, A., M. Gossen, F. Zimmermann, J. Jerecic, C. Ullmer, H. Lubbert, and H. Bujard. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. USA. 93: 10933-10938.
23. Mansuy, I. M., and H. Bujard. 2000. Tetracycline-regulated gene expression in the brain. Curr. Opin. Neurobiol. 10: 593-596.
24. Ueberham, E., R. Low, U. Ueberham, K. Schonig, H. Bujard, and R. Gebhardt. 2003. Conditional tetracycline-regulated expression of TGF-β1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology. 37: 1067-1078.
25. Sun, Y., X. Qi, D. P. Witte, E. Ponce, K. Kondoh, B. Quinn, and G. A. Grabowski. 2002. Prosaposin: threshold rescue and analysis of the "neuritogenic" region in transgenic mice. Mol. Genet. Metab. 76: 271-286.
26. Xu, Y. H., E. Ponce, Y. Sun, T. Leonova, K. Bove, D. Witte, and G. A. Grabowski. 1996. Turnover and distribution of intravenously administered mannose-terminated human acid β-glucosidase in murine and human tissues. Pediatr. Res. 39: 313-322.
27. Gordon, S., L. Lawson, S. Rabinowitz, P. R. Crocker, L. Morris, and V. H. Perry. 1992. Antigen markers of macrophage differentiation in murine tissues. Curr. Top. Microbiol. Immunol. 181: 1-37.
28. Leonova, T., and G. A. Grabowski. 2000. Fate and sorting of acid β-glucosidase in transgenic mammalian cells. Mol. Genet. Metab. 70: 281-294.
29. Liu, C., A. B. Bahnson, J. T. Dunigan, S. C. Watkins, and J. A. Barranger. 1998. Long-term expression and secretion of human glucocerebrosidase by primary murine and human myoblasts and differentiated myotubes. J. Mol. Med. 76: 773-781.
30. Du, H., M. Levine, C. Ganesa, D. P. Witte, E. S. Cole, and G. A. Grabowski. 2005. The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy. Am. J. Hum. Genet. 77: 1061-1074.
31. McEachern, K. A., J. B. Nietupski, W. L. Chuang, D. Armentano, J. Johnson, E. Hutto, G. A. Grabowski, S. H. Cheng, and J. Marshall. 2006. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J. Gene Med. 8: 719-729.